Events

UK Bioscience Forum w/ Gareth Jones & Peju Oshisanya

Intellectual Property in AI and data technologies

11:45am | 14 October 2020

The competing demands of data creation, data protection and data provision and acquisition pull data IP practice in different ways. How can we manage these competing demands to produce a result that is ultimately most beneficial for patients and the sector?

Speakers:

  • Gareth Jones, VP Intellectual Property at BenevolentAI
  • Dr Nicola Baker-Munton, Chief Executive Officer at Statagem
  • Joe Foster, COO at Mogrify
  • Tim Hoctor, Vice President of Global Professional Services at Elsevier
  • Jule Sigall, Associate General Counsel, Open Innovation, IP Group at Microsoft

→ Register here

Diversity in data for drug discovery and clinical applications

11:45am | 14 October 2020

A lack of diversity in clinical datasets is a known problem for the life sciences industry, and one that must be addressed. In this session, we will discuss what different organisations are doing to address this, and share lessons they have learned from their experiences.

Speakers:

  • Peju Oshisanya MSc, BSc (HONS), Director, Clinical Programme Leader at BenevolentAI
  • Maria Chatzou Dunford, CEO and Co-Founder at Lifebit Biotech
  • Annette Jack, Founder at Egality
  • Dr Jason Mellad, CEO at Start Codon
  • Umang Patel, Clinical Director, Babylon

→ Register here


Peju Oshisanya

Clinical Drug Development Leader & Data Diversity Advocate at BenevolentAI

Peju is an innovative operational strategy expert with over 15 years wide-ranging experience relating to strategic programme leadership, planning and management of clinical trials with responsibility for global clinical programmes. She has extensive experience in working in early drug discovery and exploratory phases focused on the transition of early stage assets to clinical development. She has held leadership positions in programme management responsible for key clinical programmes and assets within Eli Lilly, Sanofi Aventis, Pfizer and Takeda. In her current role at BenevolentAI, she is responsible for driving the asset strategy to maximise the value of both early and late phase drug development programmes.

Gareth Jones

VP Intellectual Property

Gareth Jones is one of the the world's leading intellectual property strategists (IAM Strategy 300). At BenevolentAI he is responsible for IP activities including strategy, portfolio development, competitive intelligence, fundraising and M&A diligence, patent and data licensing, and collaborations. Gareth has worked at IBM, Vodafone, Microsoft, and also at tech startup SwiftKey where he built and scaled IP operations for one of the largest UK tech exits of 2015/2016


More Posts

You Might Also Like

News
Rob Quinn to join BenevolentAI as Chief Financial Officer
Rob Quinn to join BenevolentAI as Chief Financial Officer to guide the company's growth and financial direction.
Oct 21, 2020
Blog
Data Diversity: Ten practical approaches to acquiring the right datasets Part 1
In this two-part blog, we propose ten practical approaches to improving data acquisition to encourage more inclusive research and improve the diversity of data used in drug discovery.
Oct 20, 2020
Blog
Data Diversity: Ten practical approaches to acquire the right datasets Part 2
In this two-part blog, we propose ten practical approaches to improving data acquisition to encourage more inclusive research and improve the diversity of data used in drug discovery.
Oct 20, 2020
News
NIAID releases additional data validating BenevolentAI’s hypothesis for baricitinib as a treatment for COVID-19 patients in large-scale randomised control trial
Additional data from the ACTT-2 randomised control trial shows reduced time to recovery and improved clinical outcomes for patients with COVID-19.
Oct 9, 2020
News
BenevolentAI welcomes Professor Russ Altman as scientific advisor
As a scientific advisor at BenevolentAI, Professor Russ Altman will help our scientists to further push the boundaries of machine learning applied drug discovery.
Oct 1, 2020
Blog
The Diversity Analysis Tool: Towards better Diversity in Data for Precision Medicine
As part of the data diversity initiative, our team released a simple open-source programme to evaluate the diversity of datasets and inspire others to search for solutions to drive innovation that benefits everyone.
Sep 22, 2020